Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular hyoscine butylbromide for shortening the first stage of labour in nulliparous women at term
PACTR202601774213602Phase 2Not yet recruiting
- Sponsor
- Self
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial comparing Hyoscine butylbromide with Placebo (2 arms). Primary endpoint: Difference in mean duration of active phase of labour. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
hyoscine butylbromide
Beyond the preview
Go deeper on PACTR202601774213602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202601774213602.